Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
25.7M
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
1.27M
-
Shares change
-
+1.27M
-
Total reported value, excl. options
-
$3.84M
-
Value change
-
+$3.84M
-
Number of buys
-
11
-
Price
-
$3.02
Significant Holders of Benitec Biopharma Inc. - Common Stock (BNTC) as of Q3 2023
11 filings reported holding BNTC - Benitec Biopharma Inc. - Common Stock as of Q3 2023.
Benitec Biopharma Inc. - Common Stock (BNTC) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.27M shares
of 25.7M outstanding shares and own 4.94% of the company stock.
Largest 10 shareholders include FRANKLIN RESOURCES INC (588K shares), JANUS HENDERSON GROUP PLC (206K shares), SUVRETTA CAPITAL MANAGEMENT, LLC (204K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (189K shares), CITADEL ADVISORS LLC (69.5K shares), GEODE CAPITAL MANAGEMENT, LLC (10K shares), Tower Research Capital LLC (TRC) (196 shares), RHUMBLINE ADVISERS (186 shares), UBS Group AG (109 shares), and GROUP ONE TRADING, L.P. (89 shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.